Genfit S.A. (GNFTF)

Genfit S.A. (GNFTF) Gesundheitswesen & Pipeline-Uebersicht

Genfit S.A. is a biopharmaceutical company specializing in metabolic and liver disease treatments, including Elafibranor for primary biliary cholangitis. With diagnostic solutions like NIS4 technology and partnerships with Labcorp and Genoscience Pharma, Genfit navigates the competitive biotech landscape, focusing on unmet needs in liver-related conditions.

Investmentthese

Genfit S.A. presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of drug candidates targeting liver diseases. The Phase 3 clinical trial of Elafibranor for PBC represents a near-term catalyst, with potential for market approval and revenue generation. The development of NIS4 technology for NASH diagnosis offers a longer-term growth avenue, addressing the increasing prevalence of NASH globally. However, the company's negative profit margin of -85.9% and reliance on clinical trial outcomes pose significant risks. Successful commercialization of its products and strategic partnerships are crucial for achieving profitability and shareholder value. Investors should closely monitor clinical trial results, regulatory approvals, and competitive dynamics within the liver disease treatment market.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

• Market capitalization of $0.54 billion reflects investor valuation of Genfit's pipeline and potential.
• A P/E ratio of -11.22 indicates that the company is currently unprofitable, typical for biotechnology firms in the development stage.
• Gross margin of 93.1% suggests strong potential profitability upon successful commercialization of its products.
• Beta of 1.19 indicates that the stock is slightly more volatile than the market, reflecting the inherent risks in biotechnology investments.
• The company's focus on liver diseases addresses a significant unmet medical need, driving potential for future growth.

Wettbewerber & Vergleichsunternehmen

Staerken

• Proprietary drug candidates in clinical development.
• Strong expertise in metabolic and liver diseases.
• Strategic partnerships with leading companies.
• Innovative diagnostic technologies.

Schwaechen

• High reliance on clinical trial outcomes.
• Negative profitability.
• Limited commercial infrastructure.
• Dependence on partnerships for commercialization.

Katalysatoren

• Upcoming: Results from Phase 3 clinical trial of Elafibranor for PBC expected in late 2026 or early 2027.
• Ongoing: Commercialization of NASHnext through partnership with Labcorp.
• Upcoming: Potential regulatory approval of Elafibranor for PBC in late 2027, if Phase 3 results are positive.
• Ongoing: Development of NIS4 technology for NASH diagnosis.
• Upcoming: Advancement of GNS561 through Phase 1b/2 trial for CCA with potential data release in 2027.

Risiken

• Potential: Failure of Elafibranor in Phase 3 clinical trials.
• Potential: Regulatory hurdles in obtaining approval for Elafibranor.
• Ongoing: Competition from other companies developing treatments for liver diseases.
• Ongoing: Dependence on partnerships for commercialization.
• Potential: Patent expiration on key technologies.

Wachstumschancen

• Elafibranor for Primary Biliary Cholangitis (PBC): Elafibranor, currently in Phase 3 clinical trials, represents a significant growth opportunity for Genfit. If approved, Elafibranor could address a substantial unmet need in the treatment of PBC, a chronic liver disease. The PBC market is projected to grow, driven by increased awareness and improved diagnostic methods. Successful completion of Phase 3 trials and subsequent regulatory approval could lead to significant revenue generation for Genfit, potentially starting in late 2026 or early 2027.
• NIS4 Technology for NASH Diagnosis: The development of NIS4 technology for the non-invasive diagnosis of NASH and fibrosis offers a compelling growth avenue. NASH is a rapidly growing liver disease, and early diagnosis is crucial for effective management. NIS4 aims to provide a convenient and accurate diagnostic tool, potentially capturing a significant share of the NASH diagnostics market. Commercialization of NIS4, potentially through partnerships, could contribute to Genfit's revenue growth starting in 2027.
• GNS561 for Cholangiocarcinoma (CCA): Genfit's GNS561, currently in Phase 1b/2 trial for CCA, represents a longer-term growth opportunity. CCA is a rare but aggressive cancer of the bile ducts, with limited treatment options. Successful development and commercialization of GNS561 could address a critical unmet need and generate revenue for Genfit, although this is likely several years away, potentially 2029 or later.
• Partnership with Labcorp for NASHnext: Genfit's licensing agreement with Labcorp for the commercialization of NASHnext provides a revenue stream and market access. NASHnext is a blood-based molecular diagnostic test for NASH. This partnership allows Genfit to leverage Labcorp's extensive network and expertise in diagnostics, accelerating the adoption of NASHnext and contributing to Genfit's financial performance. Revenue from this partnership is ongoing.
• Expansion into New Therapeutic Areas: Genfit could explore expansion into new therapeutic areas within metabolic and liver diseases, leveraging its expertise and infrastructure. This could involve developing new drug candidates or acquiring existing assets. Expanding the pipeline would diversify Genfit's revenue streams and reduce its reliance on individual products. This is a longer-term strategy, potentially unfolding over the next 5-10 years.

Chancen

• Growing market for NASH treatments and diagnostics.
• Expansion into new therapeutic areas.
• Potential for regulatory approval of Elafibranor.
• Increased adoption of NIS4 technology.

Risiken

• Competition from other pharmaceutical and biotechnology companies.
• Clinical trial failures.
• Regulatory hurdles.
• Patent expiration.

Wettbewerbsvorteile

• Proprietary drug candidates and diagnostic technologies protected by patents.
• Expertise in metabolic and liver diseases.
• Established partnerships with leading pharmaceutical and diagnostic companies.
• Clinical trial data demonstrating the efficacy and safety of its products.

Ueber GNFTF

Genfit S.A., established in 1999 and headquartered in Loos, France, is a biopharmaceutical company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases. The company's primary focus is on addressing significant unmet medical needs in areas such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cholangiocarcinoma (CCA). Genfit's lead product candidate, Elafibranor, is currently in Phase 3 clinical development for the treatment of PBC. Additionally, the company is developing NIS4 technology for the diagnosis of NASH and fibrosis, aiming to provide a non-invasive diagnostic tool for early detection and monitoring of disease progression. Genfit is also advancing GNS561, a drug candidate in Phase 1b/2 trial for CCA, and Nitazoxanide, in Phase 1 trial for acute-on-chronic liver failure. Genfit has established strategic collaborations, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma for the development and commercialization of GNS561 for CCA. These partnerships underscore Genfit's commitment to expanding its reach and impact in the field of liver diseases.

Was das Unternehmen tut

• Discovers and develops drug candidates for metabolic diseases.
• Focuses on treatments for liver-related diseases.
• Develops diagnostic solutions for liver conditions.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval for its products from health authorities.
• Commercializes its products through partnerships and direct sales.

Geschaeftsmodell

• Develops and patents novel drug candidates and diagnostic technologies.
• Out-licenses or partners with other companies for commercialization.
• Generates revenue through licensing fees, milestone payments, and royalties.
• Potentially generates revenue through direct sales of diagnostic products.

Branchenkontext

Genfit S.A. operates within the competitive biotechnology industry, focusing on the development of treatments and diagnostics for liver diseases. The NASH market, in particular, is experiencing significant growth due to the increasing prevalence of obesity and related metabolic disorders. Key competitors include BRIBF, BXPHF, IPHYF, JWCTF, and MLLCF, each pursuing different approaches to address liver diseases. Genfit's strategic partnerships and focus on innovative diagnostic solutions position it to capture a share of this expanding market, estimated to reach billions of dollars in the coming years.

Wichtige Kunden

• Patients suffering from metabolic and liver diseases.
• Physicians who treat patients with these conditions.
• Diagnostic laboratories that use Genfit's diagnostic products.
• Pharmaceutical companies that partner with Genfit for drug development and commercialization.

Finanzdaten

Chart & Info

Aktuelle Nachrichten

Analystenkonsens

MoonshotScore

Genfit S.A. Aktie: Wichtige Fragen beantwortet

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Popular Stocks